Skip to main content
OpenTrials
Completed

NCT Number: NCT01116024

ATS 3f Enable(tm) Aortic Bioprosthesis, Model 6000

This is a prospective, non-randomized, multi-center study designed to evaluate safety and effectiveness of the ATS 3f Enable Aortic Bioprosthesis in a patient population undergoing isolated aortic valve replacement with or without concomitant procedures. The Enable Aortic Valve is an equine pericardial stented bioprosthesis.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Heart Valve Diseases Cardiovascular Diseases Heart Diseases

Age range

21 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Medical University of Vienna, Vienna, Austria

Loading trial locations.

About this study

The ATS 3f Enable Aortic Bioprosthesis is intended for those patients whose prognosis without surgical replacement of the diseased natural valve is unacceptably poor in terms of survival and/or quality of life in the opinion of the attending physicians. For these patients, there are a number of widely accepted prosthetic heart valves in use.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • The patient requires isolated aortic valve replacement with or without concomitant procedures such as coronary artery bypass or another valve repair. (The three remaining valves must be of native tissue).
  • The patient is geographically stable and willing to return to the implant site for follow-up visits.
  • The patient has been adequately informed of risks and requirements and consent to his/her participation in the clinical study.
  • If this patient is female and of childbearing potential, patient has a negative pregnancy test within seven (7) days prior to the study procedure.

Exclusion criteria

  • The patient requires replacement of two or more valves.
  • The patient is < 20 years of age.
  • The patient has a non-cardiac major or progressive disease, which in the Investigator's experience produces an unacceptable increased risk to the patient, or results in a life expectancy of less than 24 months.
  • The patient is an intravenous drug and/or alcohol abuser.
  • The patient presents with active endocarditis or other systemic infection.
  • The patient has had previous valve replacement surgery, including previous implant and then explant of the ATS 3f Enable Aortic Bioprosthesis (Model 6000) or placement of a rigid annuloplasty ring in the mitral position.
  • The patient is participating in concomitant research studies of investigational products.
  • The patient presents with dilatation of the ascending aorta, Marfan Syndrome, Ehlers-Danlos syndrome, cystic medial degeneration, or other condition causing the ascending aorta to be irregular in geometry or physiology as seen via preoperative imaging.
  • The patient has chronic renal failure.

Treatment and study plan

ATS 3f Enable Aortic Bioprosthesis Model 6000

Device

Replacement Aortic Heart Valve

Primary outcomes

  1. Thromboembolism/Thrombosis

    Time frame: Five Years

    Valve related thromboembolism and valvular thrombosis.

    Thrombosis was defined as any thrombus attached to or near the study valve that interfered with valve function in the absence of infection. The results are reported as linearized rate (percentage of participants per patient-year)

  2. Hemorrhage/Bleeding-Anticoagulant/Antiaggregant (All and Major)

    Time frame: Five Years

    Any episode of internal or external bleeding in subjects receiving anticoagulant and/or antiaggregant therapy.

    Hemorrhage/Bleeding (No Anticoagulant/Antiaggregant):

    Any episode of internal or external bleeding in subjects not receiving anticoagulant and/or antiaggregant therapy.

    The results are reported as linearized rate (percentage of participants per patient-year).

  3. Paravalvular Leaks (All and Major)

    Time frame: Five Years

    Paravalvular leak was defined as any evidence of leakage of blood around the prosthesis (between the sewing ring and native annulus). Major Paravalvular leak was defined as any evidence of leakage of blood around the prosthesis, i.e. between the sewing ring and native annulus that requires surgical intervention.

    The results are reported as linearized rate (percentage of participants per patient-year).

  4. Endocarditis

    Time frame: Five Years

    Endocarditis was defined in the protocol as any infection involving the study valve. Any structural/non-structural valvular dysfunction, thrombosis, or embolic event associated with study valve endocarditis was captured as endocarditis only.

    The results are reported as linearized rate (percentage of participants per patient-year).

  5. Hemolysis

    Time frame: Five Years

    Blood data analysis was performed in order to identify whether particular complications and serious adverse events such as hemolysis occurred. Hemolysis in subjects with tissue valves - as evidenced by increased serum lactate dehydrogenase concentrations, decreased serum haptoglobin concentration, erythrocytopenia and reticulocytosis - is usually associated with paravalvular leakage or infection.

  6. Structural Valve Deterioration

    Time frame: Five Years

    Structural deterioration was defined as any change in the study valve function which resulted from an intrinsic abnormality that caused stenosis or regurgitation.

    There were no cases of structural deterioration reported for the study.

    The results are reported as linearized rate (percentage of participants per patient-year).

  7. Non-Structural Dysfunction

    Time frame: Five Years

    Any abnormality resulting in stenosis or regurgitation at the operated valve that is not intrinsic to the valve itself. Non-structural dysfunction refers to non-structural problems that result in dysfunction of an operated valve exclusive of thrombosis and infection diagnosed by reoperation, autopsy, or clinical investigation.

    The results are reported as linearized rate (percentage of participants per patient-year).

  8. Re-operation, Explant, Repair

    Time frame: Five Years

    Reoperation was defined in the protocol as any operation to repair, alter, or replace the study valve. Included is reoperation for repair of paravalvular leak and explant.

    The results are reported as linearized rate (percentage of participants per patient-year).

  9. Effectiveness Endpoint - NYHA Classification, Hemodynamic Performance

    Time frame: Five Years

    New York Heart Association (NYHA) classification to asses improvement of the cardiac status, Hemodynamic Performance analysis based on Doppler echocardiographic studies.

    Class I: Patients with cardiac disease but without limitations of ordinary activity.

    Class II: Patients with cardiac disease resulting in slight limitation of physical activity. Comfortable at rest. Ordinary physical activity results in fatigue, palpitation, dyspnea or anginal pain.

    Class III: Patients with cardiac disease resulting in marked limitation of physical activity. They are comfortable at rest. Less than ordinary physical activity results in fatigue, palpitations or anginal pain.

    Class IV: Patients with cardiac disease resulting in inability to carry out any physical activity without discomfort. Symptoms of cardiac insufficiency or anginal syndrome may be present even at rest. If any physical activity is undertaken discomfort is increased.

  10. Hemodynamic

    Time frame: Five Years

    Mean and peak pressure gradients from discharge through 5 years follow up. The gradient represents the difference in blood pressure across the valve.

  11. Hemodynamics - Effective Orifice Area

    Time frame: Five Years

    Effective orifice area (EOA) data.

    The effective orifice area is a measure of how much the heart valve prosthesis impedes blood flow through the aortic valve.

  12. Hemodynamics - Effective Orifice Area Index

    Time frame: Five Years

    The effective orifice area index is a measure of how much the heart valve prosthesis impedes blood flow through the aortic valve.

Sponsors and collaborators

Lead sponsor

Medtronic Cardiovascular

Industry

Registry information

Acronym: Enable

Important dates

Study start
2006
Primary completion
2010
Study completion
2012
First posted
May 4, 2010
Registry last updated
Jun 26, 2018

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.